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Purpose: Rett syndrome is a severe neurodevelopmental disorder in females. 
Most have mutations in the methyl-CpG-binding protein 2 (MECP2) gene (80-
90%). Epilepsy is a significant commonly accompanied feature in Rett syndrome. 
Our study was aimed at comprehensive analysis of genetic and clinical features in 
Rett syndrome patients, especially in regards to epileptic features. Materials and 
Methods: We retrospectively reviewed 20 patients who were diagnosed with 
MECP2 mutations at Severance Children’s Hospital between January 1995 and 
July 2010. All patients met clinical criteria for Rett syndrome. Evaluations in-
cluded clinical features, epilepsy classification, electroencephalography analysis, 
and treatment of seizures. Results: Ages ranged from 3.6 to 14.3 years (7.7±2.6). 
Fourteen different types of MECP2 mutations were found, including a novel in-
frame mutation (1153-1188 del36). Fourteen of these patients (70.0%) had epi-
lepsy, and the average age of seizure onset was 3.0±1.8 years. Epilepsy was di-
verse, including partial seizure in four patients (28.5%), secondarily generalized 
seizure in six (42.8%), generalized tonic seizure in two (14.3%), Lennox-Gastaut 
syndrome in one (7.1%), and myoclonic status in non-progressive encephalopa-
thy in one (7.1%). Motor functions were delayed so that only 10 patients (50.0%) 
were able to walk independently: five (35.8%) in the epilepsy group and five 
(83.3%) in the non-epilepsy group. Average developmental scale was 33.5±32.8 
in the epilepsy group and 44.4±21.2 in the non-epilepsy group. A clear genotype-
phenotype correlation was not found. Conclusion: There is a tendency for more 
serious motor impairment and cognitive deterioration in Rett syndrome patients 
with epilepsy.
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INTRODUCTION
Rett syndrome is an X-linked dominant severe neurodevelopmental disorder, first 
described in 1966 by Dr. Andreas Rett. It affects one in 10,000-15,000 female 
births worldwide and is the second most common cause of mental retardation in 
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were analyzed based on background activity and epilepti-
form discharges. Background activity was categorized ac-
cording to the EEG classification system proposed by Syn-
ek.7 The determining factor of improvement in seizure 
frequency was defined as a reduction greater than 50%.
Statistical analysis of nonparametric measures was con-
ducted using SAS version 9.2 (Statistical Analysis System, 
Institute Inc., Cary, NC, USA). Griffiths Mental Develop-
ment Scales, a head circumference below the 10th percentile, 
ambulation ability, EEG background and epileptiform dis-
charges were compared between an epilepsy and a non-epi-
lepsy group. Mann-Whitney U-test was performed to ana-
lyze developmental scale, and the other categorical variables 
were analyzed using Chi-square test or Fisher’s exact test. 
Mutation analysis 
Analyses of MECP2 mutations were performed by poly-
merase chain reaction (PCR) and direct sequencing. Patients’ 
genomic DNAs were extracted from peripheral blood, and 
four exons of the MECP2 gene were amplified by PCR. 
The primer sequence was designed by the Primer3 pro-
gram. The PCR conditions were as follows: the total vol-
ume was 20 μL; the weight of genomic DNA was 100 ng; 
the concentrations of each primer and deoxynucleotide tri-
phosphate were 10 pM and 200 μM respectively; 2X reac-
tion buffer (500 mM KCl, 2X 100 mM Tris HCl: pH 9.0, 
1% Trion X-100) and 1 U Taq polymerase (Cosmo, Seoul, 
Korea) were used; during the first step, denaturation was 
performed at 94°C for 5 minutes and repeated 35 times for 
1 minute at 94°C; annealing was done at 72°C for 30 sec-
onds; and the last step, extension, was done at 72°C for 7 
minutes. For the analysis of the amplified products, agarose 
gel electrophoresis at 135 V was done for 10 minutes. We 
purified PCR products using the Cosmo PCR purification 
kit (Cosmo) and performed DNA sequencing using a DNA 
sequencer (Life Technologies, Foster City, CA, USA) and 
the Life Technologies PRISM dye terminator cycle se-
quencing reaction kit (PerkinElmer, Waltham, MA, USA) 
with the same sequencing primer used in the PCR process. 






The ages of 20 patients ranged from 3.6 to 14.3 years (7.7±2.6 
girls. Patients show normal development after birth during 
the first six months or more, but thereafter show progres-
sive regression in cognition, language, and purposeful hand 
skills. Deceleration in head circumference and stereotypic 
hand movement are typically characteristic. Seizure, scolio-
sis, gait apraxia, and breathing disturbances are also com-
mon.1 Among these symptoms, seizure occurs in 70-90% 
of Rett syndrome patients, usually in later stages of the dis-
ease after regression.1 Epilepsy can be a major factor in 
both disease prognosis as well as quality of life. 
Mutations in the methyl-CpG-binding protein 2 (MECP2) 
gene were recognized as causes of Rett syndrome in 1999,2 
identified in 90-95% cases with typical Rett syndrome.3 
The MECP2 gene is located at the q28 locus on the X chro-
mosome and functions as a regulator of gene transcription 
in neurons that are important in synapses and neuronal 
plasticity.4,5 
In this study, we analyzed MECP2 mutations in 20 Kore-
an Rett syndrome patients and characterized the patients’ 




A retrospective review was performed on patients who vis-
ited Severance Children’s Hospital in clinical suspicion of 
Rett syndrome from January 1995 to July 2010. We identi-
fied twenty patients who met the revised diagnostic criteria 
for classical and variant Rett syndrome defined by Hag-
berg, et al.1 and revealed MECP2 mutations therein. 
 
Clinical evaluation
Demographic data concerning the patients’ age, gender, and 
birth history were collected from medical records, and clin-
ical symptoms, including hand movement, language, am-
bulatory capacity, and seizure profile, were analyzed. The 
results of the MECP2 mutation analyses, electroencepha-
lography (EEG), extended video EEG monitoring, and 
brain magnetic resonance imaging (MRI) were reviewed. 
All 20 patients underwent brain MRI, 19 underwent EEG, 
and 6 underwent additional extended video EEG monitor-
ing. Concerning epilepsy, we recorded the age of seizure 
onset, the type of seizures, as well as the administration of 
antiepileptic drugs and dietary therapy. Epilepsy classifica-
tion was documented according to the criteria of the Inter-
national League Against Epilepsy (ILAE).6 EEG features 
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Characteristics of epilepsy
The mean age of the epilepsy group was 8.4±2.6 years and 
that of the non epilepsy group was 6.1±1.4 years. The aver-
age age of seizure onset was 3.0±1.8 years. In the epilepsy 
group, three patients (21.4%) had their first seizure between 
1 and 2 years of age, three patients (21.4%) between 2 and 
3 years, five patients (35.7%) between 3 and 5 years, and 
three patients (21.4%) above 5 years.     
Various types of seizures were presented in the epilepsy 
group. Secondary generalized seizures were found in six 
patients (42.8%), partial seizures in four (28.5%), general-
ized seizures in two (14.3%), Lennox-Gastaut syndrome 
(LGS) in one (7.1%), and myoclonic status in non-progres-
sive encephalopathy (MSNE) in one (7.1%). Four patients 
(28.6%) had seizures daily; two patients (14.3%) had less 
than seven seizures per week; five (35.4%) had seizures 
less than four times a month; and three patients (21.4%) 
rarely had seizures. 
EEG showed abnormalities in most patients, including 
those in the non-epilepsy group. Only one patient in the 
non-epilepsy group (N4) showed a normal EEG pattern, 
and two patients (E1 and E4) in the epilepsy group showed 
no epileptiform discharges after effective anti-epileptic 
drug (AED) treatment. In patients with abnormal EEG, 
slow background and epileptiform discharges were promi-
nent in centro-parietal areas. EEG characteristics are ex-
plained in Table 2. Categorized EEG background severity 
and appearance of epileptiform discharges did not show 
any statistical difference between both groups (p=1.00, 
p=1.00). 
Thirteen patients (92.9%) in the epilepsy group were 
treated with AEDs. The average number of AEDs used was 
2.2 (range: 1-4). The most frequently used drug was valpro-
ic acid, which was used in 10 patients (76.9%), followed by 
lamotrigine in six patients (46.2%). Two patients (14.3%) 
were placed on ketogenic diet therapy. The overall results 
of the treatments were favorable. Six patients (42.9%) be-
came seizure free, four patients (28.6%) showed improve-
ment with seizure frequency reduction rates above 50%, 
years). The mean follow-up duration was 46 months (range, 
15-120 months). Demographic and clinical features are pre-
sented in Table 1. All patients were female. No patient had 
perinatal brain damage. Brain MRI showed no specific ab-
normalities except for brain volume reduction. Fourteen 
(70.0%) out of twenty patients, whom we grouped as the 
epilepsy group, had epilepsy. The other six patients were 
grouped in the non-epilepsy group. Psychomotor develop-
mental delay was observed in all subjects to various de-
grees. Nineteen patients could not generate any meaningful 
words. Only one exceptional patient was able to make about 
ten words. Due to delayed motor function, only ten patients 
were able to walk independently: five patients (35.8%) in 
the epilepsy group and five patients (83.3%) in the non-epi-
lepsy group (p=0.14). The average developmental scale 
score was 33.5±32.8 in the epilepsy group and 44.4±21.2 in 
the non-epilepsy group (Mann-Whitney U-test, p=0.14). 
Developmental scale scores ranged from 6.7 to 100.0. The 
patient who scored 100.0 (E2) had late deterioration after 
she had fully developed. Patients whose head circumference 
was below the 10th percentile accounted for 20.0% of all 
patients, 21.4% of the epilepsy group and 16.7% of the non-
epilepsy group (p=1.00). All patients showed stereotypical 
“washing hand” movements.  
MECP2 mutations
We identified MECP2 mutations in all 20 Rett syndrome pa-
tients. The mutations consisted of 14 distinct types, including 
seven missense, four nonsense, and three frameshift muta-
tions. The missense mutations were T158M, R306C, L100V, 
R106W, F157L, R133C, and P302R, all of which were re-
ported in previous Rett syndrome studies. The nonsense mu-
tations consisted of R294X, A255X, Q128X, and Q406X. 
Four of five patients who showed nonsense mutations had 
epilepsy. There were three frameshift mutations which were 
806delG, 1153del36, and 1157del41. The 1153del36 muta-
tion was a novel mutation. Among fourteen mutations, 
T158M (20.0%), R306C (15.0%) and R294X (10.0%) 
were most frequent. 
Table 1. Statistical Analysis between the Epilepsy and Non-Epilepsy Group
Total (n=20) Epilepsy group (n=14) Non-epilepsy group (n=6) p value
Age (yr, mean±SD) 7.7±2.6 8.4±2.6 6.1±1.4 0.20
Preserved ambulation, n (%) 10 (50.0) 5 (35.8) 5 (83.3) 0.14
Developmental scales, (mean±SD) 37.3±27.0 33.5±29.7 44.4±19.4 0.14
Head circumference 
  (% of below 10 percentile)
20.0 21.4 16.7 1.00
SD, standard deviation. 
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is thought to be related to a difference in the range of the 
patients’ ages, as there was a demonstratively younger pa-
tient age range (3.6-14.3 years) in our study compared to 
those in the USA study (0.7-64 years). 
An occurrence of epilepsy in Rett syndrome is closely 
linked to early neurodevelopmental outcomes and poor func-
tional abilities such as ambulation and hand use.11 We ob-
served a tendency of lower ability of ambulation and poorer 
development in our epilepsy group than in our non-epilepsy 
group (Table 1), though statistical correlation was not found 
in both aspects.   
EEG patterns in Rett syndrome were described in the 
early years of research, and a definite diagnostic pattern re-
mains to be established. EEG can not only vary from one 
patient to another but also within different stages of disease 
progression. EEG usually shows normal patterns up to the 
and four patients (28.6%) showed reduction rates under 
50% (Table 2).
DISCUSSION
Epilepsy is a significant symptom in Rett syndrome in re-
gards to its negative effects on quality of life and disease 
morbidity.8 In our study, the incidence of epilepsy in Rett 
syndrome patients was 70.0%. A recent USA study reported 
an epilepsy incidence of 60% in 602 patients9 and an Israeli 
study reported an incidence of 72% in 97 patients.10 Sei-
zures in Rett syndrome have been described as benign.9,12 
They usually appear in stage III (usually after 3 years of 
age) and rarely occur after the age of twenty.1,9 In compari-
son to our study, the discrepancy in the reported incidences 














E1 6y11m L100V 1y5m P2G Grade 3 No Possible 17.0 ZSM Seizure free
E3 6y6m R106W 2y5m Partial Grade 2 C-P spike Possible 12.5 OXC, VPA, MAD Seizure free
E13 9y15m F157L 6y10m P2G Grade 3 Multifocal Impossible 8.3 TPM, VPA, LMT Improved
E2 14y3m T158M 5y LGS Grade 2 C-P spike Possible 100.0
VPA, LMT, PB, 
TPM, KGD
Not improved
E5 13y10m T158M 3y GT Grade 3 C-P spike Impossible VPA, VGB, LMT Seizure free
E4 5y R306C 3y Partial Grade 3 No Impossible 33.3 Tapered out Seizure free
E7 6y5m R306C 3y9m P2G Grade 1 C-P spike Impossible 70.0 VPA, LMT Not improved
E9 8y3m R306C 5y Partial Grade 1 Multifocal Possible 64.0 OXC Seizure free
E10 11y10m Q128X 1y6m GT Grade 2 Multifocal Impossible VPA, TPM Improved
E6 4y1m A255X 2y MSNE Grade 3 Multifocal Impossible VPA Not improved
E8 9y11m R294X 3y P2G Impossible 6.7 VPA Not improved
E11 11y3m Q406X 4y7m P2G Grade 2 Multifocal Impossible 10.0






2y7m P2G Grade 2 Multifocal Impossible 13.6






1y10m Partial Grade 2 Multifocal Possible Refused Improved
N4 5y6m R133C No No Grade 1 No Possible 72.5 No
N1 6y11m T158M No No Grade 3 C-P spike Possible 31.0 No
N2 6y T158M No No Grade 2 Multifocal Impossible 37.4 No
N5 7y7m P302R No No Grade 1 C-P spike Possible 19.3 No




No No Grade 2 Multifocal Possible 68.0 No
MECP2, methyl-CpG-binding protein 2; BG, background; ED, epileptiform discharges; E, epilepsy group; N, non-epilepsy group; P2G, partial seizure with 
secondary generalization; LGS, Lennox-Gastaut syndrome; GT, generalized tonic; MSNE, myoclonic status in non-progressive encephalopathy; C-P, centro-
parietal; CLB, clobazam; LMT, lamotrigine; OXC, oxcarbazepine; PB, Phenobarbital; TPM, topiramate; VPA, valproic acid; ZSM, zonisamide; KGD, ketogenic 
diet; MAD, modified Atkins diet; EEG, electroencephalography; VGB, vigabatrin.
Background abnormality was classified by the dominant wave proposed by Synek.7 Grade 1: dominant alpha activity with some scattered theta activity, 
Grade 2: dominant theta activity, generally reactive, Grade 3: dominant widespread delta activity or small amplitude, diffuse, irregular delta activity, non 
reactive. The determining factor of improvement in seizure outcomes was defined as a reduction greater than 50%. 
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clinical features. One had epilepsy and one did not. The 
1157del41 was previously recognized as an MECP2 muta-
tion in a Korean population by Chae, et al.,21 and the clini-
cal features thereof were similar to our patient, in respect to 
the non-epilepsy presenter. The 1153del36 mutation was a 
newly indentified de novo mutation found in our study. The 
patient of this mutation was characterized by typical fea-
tures of Rett syndrome with an early onset of partial seizure 
at the age of 1 year and 10 months. Her seizures were self-
remitted without AEDs though her neurodevelopmental 
function was still severely compromised. Glaze, et al.9 re-
ported a higher incidence of seizures (74%) with the T158M 
mutation and a lower incidence of seizures (49%) with the 
R255X mutation. We were not able to make such a correla-
tion between the mutation genotype and the prevalence or se-
verity of seizures. This may be due to our small sample size.  
Because of the limited sample size and short follow-up 
duration, a genotype-phenotype correlation was not made. 
However, our results will be helpful in understanding epi-
lepsy in Rett syndrome patients. In addition, we were able 
to find a tendency of more serious motor impairment and 
cognitive deterioration in Rett syndrome patients with epi-
lepsy. Further studies on MECP2 gene function and muta-
tions on a larger scale will provide a better understanding of 
the pathogenesis and natural courses of Rett syndrome.
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